How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Ixekizumab for treating axial spondyloarthritis

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about ixekizumab

Marketing authorisation indication

2.1 Ixekizumab (Taltz, Eli Lily) is indicated for 'the treatment of adult patients with active ankylosing spondylitis [radiographic axial spondyloarthritis] who have responded inadequately to conventional therapy, and active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The list price of ixekizumab is £1,125 for 1 pre-filled syringe containing 80 mg per 1 ml solution (excluding VAT; British National Formulary [BNF], accessed March 2021). The annual cost is £16,875 for 15 injections in the year 1 and £14,625 for 13 injections in year 2 (excluding VAT; British National Formulary [BNF], accessed March 2021).

2.4 The company has a commercial arrangement. This makes ixekizumab available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.